Clinical trial
Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With…
NCT00143663 · Takeda, Industry · Completed
Key facts
| NCT number | NCT00143663 |
|---|---|
| Title | Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol |
| Official title | A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 100 mg Versus Placebo in Subjects With Primary Hypercholesterolemia |
| Lead sponsor | Takeda, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Dyslipidemia |
| Intervention type | Drug |
| Interventions | Lapaquistat Acetate, Placebo |
| Enrollment | 361 |
| Start date | Sep 1, 2005 |
| Primary completion | Apr 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Sep 2, 2005 |
| Last update posted | May 24, 2012 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: